Skip to main content

ASH Annual Meeting 2025

ASH Annual Meeting 2025

6–9 December | Orlando

We bring you all the news, clinical updates, and expert insights from the 2025 ASH annual meeting for hematology professionals worldwide, with discussions covering sickle cell disease, multiple myeloma, lymphoma, transplants and more.

Reassurance for pregnant SCD patients taking hydroxyurea

Taking hydroxyurea for sickle cell disease shortly before or during pregnancy may not be associated with worse maternal or neonatal outcomes.

Read more

Oncology Update

Covering the latest advances and keeping your practice up to date. Receive newsletters personally curated for the busy oncologist.

HOPE-B shows durable response to hemophilia B gene therapy

Five-year follow-up demonstrates that a single dose of gene therapy has achieved long-term factor IX expression and low rates of bleeding in men with hemophilia B.

First-line fixed-duration CLL regimens noninferior to continuous therapy

Fixed-duration regimens of venetoclax with obinutuzumab or ibrutinib are noninferior to continuous ibrutinib for patients with treatment-naïve chronic lymphocytic leukemia.

More HLA mismatches possible without poorer transplant outcomes

Hematopoietic stem cell transplantation from donors with 2 or more HLA mismatches does not adversely affect 1-year survival when post-transplant cyclophosphamide is used as prophylaxis against graft-versus-host disease.

Pirtobrutinib supported for treatment-naïve CLL/SLL

Pirtobrutinib significantly prolongs progression-free survival in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared with standard treatment.

MajesTEC-3 supports teclistamab–daratumumab in MM

Phase 3 trial data show a significant improvement in progression-free survival with use of teclistamab plus daratumumab for patients with relapsed or refractory multiple myeloma.

Read more

Early MRD negativity with in vivo CAR T-cell therapy in R/R MM

All patients who received the intravenous CAR T-cell therapy KLN-1010 in the phase 1 inMMyCAR study achieved minimal residual disease negativity after a month.

Pacritinib treatment feasible in transplant-eligible myelofibrosis patients

Treatment with pacritinib prior to allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis is well tolerated and effective.

Adding epcoritamab to R2 yields better outcomes in R/R FL

Supplementing rituximab plus lenalidomide with epcoritamab offers a significant advantage in patients with relapsed or refractory follicular lymphoma.

Long-term outcomes and late effects after HCT in sickle cell disease

Hematopoietic stem cell transplantation for sickle cell disease offers excellent long-term survival, especially in younger patients and when a fully matched related donor is used.

Racial differences in AML survival independent of cytogenetics

Black patients with acute myeloid leukemia are diagnosed at a younger age than White patients and have significantly poorer survival, regardless of their cytogenetic risk profile.

Chemotherapy-free treatment superior in Ph-positive ALL

The combination of ponatinib plus blinatumomab is more effective than imatinib plus chemotherapy in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.

HOVON902 demonstrates value of serial ctDNA monitoring in DLBCL

Serial measurement of circulating tumor DNA is a powerful predictor of treatment response and relapse risk in patients with diffuse large B-cell lymphoma.

Improving detection of iron deficiency in pregnancy

A standardized approach combining ferritin testing with standard hemoglobin tests improves detection of iron deficiency in pregnancy.

IV iron beneficial for anemia during acute infections

Among patients with iron deficiency anemia, intravenous iron treatment during hospitalization for acute infections improves survival.

Read more

New immunologic risk model developed for MDS

A new risk score model based on the immune-related transcriptome significantly improves prognostic stratification in myelodysplastic syndromes.

HARMONY confirms MRD as a robust surrogate endpoint in AML

Measurable residual disease after induction therapy is a strong predictor of survival in adults with acute myeloid leukemia.

Celebrating 25 years of TKIs in CML

We reflect on a key breakthough in the treatment of CML with Dr. Jorge Cortes, who has been involved in the development of TKIs since the early days.

Listen now
Podcast

Stay up to date with more from Springer Medicine

The AML expert series

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing and treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
SPONSORED

CAR T-cell therapy medical education hub

This hub presents a curated selection of educational materials focused on the latest clinically relevant topics related to the use of chimeric antigen receptor (CAR) T‑cell therapy for the treatment of relapsed/refractory (R/R) diffuse large B‑cell lymphoma (DLBCL) and R/R follicular lymphoma (FL).

This content has been developed in collaboration with and funded by the sponsor Novartis Pharma AG and is not intended for healthcare professionals based in the UK and US.

Sponsored by:
  • Novartis Pharma AG

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Image Credits
Doctor and pregnant woman at hospital/© Syda Productions / stock.adobe.com (symbolic image with models), Close-up of subcutaneous injection syringe/© Laures / Getty Images / iStock, Vector illustration of intravenous therapy/© Tarchyshnik / Getty Images / iStock, Medicine Matters Podcast promo image/© Springer Medizin GmbH, Leukemia background in bright colors, including white and red blood cells in realistic style/© Double Brain/Shutterstock.com, T-cell expressing chimeric antigen receptor (CAR) in the cell membrane; DNA is exposed from the T-cell to highlight the genetic engineering involved in creating CAR T-cells/© LoveLive/stock.adobe.com, Aplastic Anemia/© Springer Healthcare IME